The R.S. McLaughlin Durham Regional Cancer Centre (DRCC) at Lakeridge Health unveiled a new, technologically-advanced robot that prepares injectable cancer treatments. The new robot is part of a transformation of oncology pharmacy services at the DRCC.
“As one of Ontario’s leading cancer programs, the R.S. McLaughlin Durham Regional Cancer Centre has some of the lowest cancer treatment wait times and a well-earned reputation for high-quality care,” said Matthew Anderson, President and CEO, Lakeridge Health. “The modern pharmacy space and state-of-the art robotic and other technologies ensure patients will continue to have access to exceptional cancer treatment here in Durham Region.”
Lakeridge Health is home to one of only five Robotic Intravenous Automation (RIVA) systems in Canada. The new RIVA robot is part of a major renewal of the DRCC’s pharmacy which includes an upgraded retail pharmacy space, new consultation kiosks and other enhancements to ensure the safest and most sterile environment to prepare chemotherapy treatments.
“We are very excited to share this news with the community,” said Kirsten Burgomaster, Interim Regional Vice-President, Cancer Services. “This new technology adds to the range of services already offered to Durham residents who rely on the Centre for various cancer services such as diagnosis, treatment and follow-up care close to home.”
The RIVA robot, developed by ARxIUM, uses a robotic arm to help pharmacy professionals prepare chemotherapy treatment in syringes and IV bags. The robot’s barcode tracking system, quality assurance and automated compounding capabilities will enhance safety for patients at DRCC’s systemic suite, which cares for 80 to 90 people a day and more than 17,600 annually.